Immix Biopharma, Inc. Overview
Pro stress-test →Immix Biopharma is a clinical-stage biopharmaceutical company engaged in developing chimeric antigen receptor cell therapy (CAR-T) in light chain Amyloidosis and immune-mediated diseases. The company's lead asset, NXC-201, has demonstrated overall response rates of 100% in AL Amyloidosis and 95% in multiple myeloma in ongoing clinical trials. The company represents a high-risk, high-reward opportunity focused on orphan indications with significant unmet medical need.
Strategic Profile
Pro stress-test →Immix Biopharma has established a strong foothold in advancing cell therapies, building on one of the largest clinical datasets in the cell therapy industry. NXC-201 has the potential to be the world's first "Single-Day CRS" CAR-T, enabling faster patient return home. The company has secured FDA Orphan Drug Designations and Breakthrough Therapy Designation, positioning it favorably for accelerated regulatory pathways.
Competitive Landscape
Pro stress-test →Immix competes in the CAR-T cell therapy space against established players including Juno Therapeutics (Celgene), Kite Pharma (Gilead), and Novartis, as well as emerging clinical-stage competitors. Key differentiation lies in NXC-201's single-day CRS profile, orphan indication focus, and exceptional response rates in an underserved market with no current approved alternatives.
Industry Context
Immix Biopharma, Inc. operates in Biopharmaceuticals / Cell & Gene Therapy.
Key facts
Founded: 2012 · Headquarters: Los Angeles, US · Market cap: $68.6M